News | August 12, 2011

U.K.'s First Total Artificial Heart Patient Discharged Using Freedom Portable Driver

August 12, 2011 — SynCardia Systems Inc., manufacturer of the temporary Total Artificial Heart (TAH), said Aug. 2, Papworth Hospital in Cambridge discharged the United Kingdom's first TAH patient. He was sent home to wait for a matching donor heart with his wife and 5-year-old son using the Freedom portable driver.

"Two years ago I was cycling nine miles to work and nine miles back every day, but by the time I was admitted to hospital, I was struggling to walk even a few yards," said patient Matthew Green. "I am really excited about going home and just being able to do the everyday things that I haven't been able to do for such a long time, such as playing in the garden with my son and cooking a meal for my family."

Green, 40, suffered from arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease resulting in arrhythmia, heart failure and sudden death. His health had been declining over recent years, with a heart transplant being his only option.

"Matthew's condition was deteriorating rapidly and we discussed with him the possibility of receiving this device, because without it he may not have survived the wait until a suitable donor heart could be found for him," said Steven Tsui, consultant cardiothoracic surgeon and director of the transplant service. "The operation went extremely well and Matthew has made an excellent recovery."

On June 9, Green became the first patient in the United Kingdom to receive the Total Artificial Heart. Two months later, he was discharged from the hospital using the Freedom portable driver. Weighing 13.5 pounds, including two onboard lithium-ion batteries, it is the world's first wearable portable driver designed to power the TAH both inside and outside the hospital. The driver is CE approved for use in Europe and undergoing a U.S. Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical study in the United States.

Papworth Hospital is the first and only hospital in the UK certified to implant the TAH. The hospital performed the UK's first heart transplant in 1979 and has been using mechanical devices to support patients with end-stage heart failure since the 1980s.

For more information: www.syncardia.com

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...